The US Food and Drug Administration approved two therapies for the treatment of sickle cell disease. One of the treatments, Casgevy, uses CRISPR gene editing. The treatment’s developers, CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX), are both trending on Yahoo Finance. Lululemon shares are soaring on its better-than-expected third-quarter results. Other trending tickers on Yahoo Finance include Paramount Global (PARA), RH (RH), and Broadcom (AVGO).

Top guests on Yahoo Finance Live today include:
3:05 p.m. ET - Reshma Kewalramani, CEO of Vertex Pharmaceuticals
3:20 p.m. ET - Julia Pollak, ZipRecruiter Chief Economist
3:30 p.m. ET - Jay Woods, Freedom Capital Markets Chief Global Strategist
3:45 p.m. ET - Jason Kupferberg, Bank of America Senior Equity Research Analyst
4:05 p.m. ET - Stephen Gengaro, Stifel Managing Director